Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma

Table 4

FA, CI, and DRI values for defactinib and dasatinib combination treatment in DSRCT, ES, ARMS, and ERMS cell lines.

Subtype	Cell line	Fraction IC50	FA-value (mean ± SD)	CI	DRI (def; das)
DSRCT	JN-DSRCT-1	0.0625	0.101 ± 0.05	0.463	(9.30; 2.81)
		0.125	0.202 ± 0.08	0.517	(6.02; 2.85)
		0.25	0.411 ± 0.10	0.532	(4.16; 3.43)
		0.5	0.736 ± 0.08	0.485	(3.24; 5.69)
		1	0.849 ± 0.01	0.685	(2.02; 5.23)
		2	0.870 ± 0.01	1.264	(1.07; 3.04)
		4	0.873 ± 0.01	2.500	(0.54; 1.56)
ES	TC32	0.0625	0.366 ± 0.06	0.576	(12.7; 2.01)
		0.125	0.409 ± 0.13	0.783	(7.28; 1.55)
		0.25	0.484 ± 0.17	0.844	(4.56; 1.60)
		0.5	0.562 ± 0.15	0.939	(2.87; 1.69)
		1	0.671 ± 0.12	0.885	(2.02; 2.56)
		2	0.758 ± 0.07	1.000	(1.39; 3.56)
		4	0.774 ± 0.07	1.802	(0.74; 2.20)
ARMS	Rh30	0.0625	0.155 ± 0.16	0.334	(18.8; 3.57)
		0.125	0.176 ± 0.09	0.514	(9.93; 2.42)
		0.25	0.246 ± 0.14	0.515	(6.16; 2.84)
		0.5	0.440 ± 0.12	0.332	(4.73; 8.30)
		1	0.629 ± 0.03	0.342	(3.44; 19.5)
		2	0.741 ± 0.02	0.486	(2.22; 27.9)
		4	0.704 ± 0.02	1.088	(1.02; 9.62)
ERMS	RD	0.0625	0.239 ± 0.03	0.083	(22.9; 25.6)
		0.125	0.218 ± 0.03	0.177	(10.7; 11.9)
		0.25	0.281 ± 0.02	0.291	(6.50; 7.29)
		0.5	0.415 ± 0.03	0.411	(4.56; 5.23)
		1	0.557 ± 0.04	0.587	(3.15; 3.70)
		2	0.720 ± 0.03	0.876	(1.55; 4.37)
		4	0.758 ± 0.03	1.564	(0.86; 2.46)

DSRCT: desmoplastic small round cell tumor; ES : Ewing sarcoma; ARMS: alveolar rhabdomyosarcoma; ERMS: embryonal rhabdomyosarcoma; FA-value: the fraction of cell viability affected by treatment; CI: combination index; DRI: dose reduction index; def: defactinib; das: dasatinib.